Marcy Behar Bolster, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rheumatology | 28 | 2024 | 615 | 7.220 |
Why?
|
Bone Density Conservation Agents | 9 | 2024 | 795 | 2.100 |
Why?
|
Osteoporosis | 8 | 2023 | 1606 | 1.930 |
Why?
|
Scleroderma, Systemic | 24 | 2024 | 344 | 1.830 |
Why?
|
Rheumatic Diseases | 9 | 2024 | 649 | 1.750 |
Why?
|
Diphosphonates | 5 | 2024 | 636 | 1.690 |
Why?
|
Arthritis, Rheumatoid | 23 | 2024 | 3763 | 1.600 |
Why?
|
Education, Medical, Graduate | 9 | 2023 | 2373 | 1.240 |
Why?
|
Fellowships and Scholarships | 9 | 2023 | 1117 | 1.180 |
Why?
|
Osteoporotic Fractures | 2 | 2022 | 411 | 0.930 |
Why?
|
Telemedicine | 5 | 2024 | 3051 | 0.890 |
Why?
|
Lung Diseases, Interstitial | 9 | 2024 | 918 | 0.860 |
Why?
|
Antirheumatic Agents | 11 | 2024 | 1372 | 0.850 |
Why?
|
Imidazoles | 2 | 2024 | 1180 | 0.760 |
Why?
|
Fractures, Bone | 2 | 2023 | 2046 | 0.750 |
Why?
|
Curriculum | 13 | 2023 | 3743 | 0.700 |
Why?
|
Muscle Weakness | 1 | 2023 | 412 | 0.690 |
Why?
|
Education, Distance | 1 | 2023 | 261 | 0.670 |
Why?
|
Clinical Competence | 8 | 2023 | 4792 | 0.650 |
Why?
|
Autoimmune Diseases | 6 | 2024 | 2244 | 0.640 |
Why?
|
Glucocorticoids | 6 | 2024 | 2161 | 0.590 |
Why?
|
Hypertension, Pulmonary | 10 | 2018 | 1578 | 0.580 |
Why?
|
Hip Fractures | 1 | 2024 | 988 | 0.520 |
Why?
|
Fractures, Stress | 2 | 2015 | 202 | 0.500 |
Why?
|
Pain Threshold | 6 | 2023 | 604 | 0.500 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1403 | 0.490 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2015 | 118 | 0.460 |
Why?
|
Internal Medicine | 2 | 2022 | 1051 | 0.460 |
Why?
|
Orthopedics | 1 | 2022 | 898 | 0.450 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 823 | 0.440 |
Why?
|
Fibromyalgia | 3 | 2022 | 405 | 0.440 |
Why?
|
Fasciitis | 2 | 2009 | 67 | 0.420 |
Why?
|
Aromatase Inhibitors | 1 | 2016 | 513 | 0.400 |
Why?
|
Internship and Residency | 4 | 2022 | 5880 | 0.380 |
Why?
|
Faculty, Medical | 2 | 2020 | 1203 | 0.370 |
Why?
|
Pandemics | 5 | 2024 | 8654 | 0.370 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 532 | 0.370 |
Why?
|
Inpatients | 4 | 2023 | 2548 | 0.350 |
Why?
|
Humans | 97 | 2024 | 761504 | 0.340 |
Why?
|
Preventive Health Services | 1 | 2014 | 567 | 0.340 |
Why?
|
Tibia | 1 | 2015 | 1070 | 0.330 |
Why?
|
Eosinophilia | 2 | 2009 | 560 | 0.320 |
Why?
|
Interprofessional Relations | 1 | 2015 | 990 | 0.320 |
Why?
|
Vertebroplasty | 1 | 2010 | 78 | 0.310 |
Why?
|
Physician Assistants | 3 | 2019 | 191 | 0.310 |
Why?
|
Adrenal Cortex Hormones | 2 | 2016 | 1880 | 0.300 |
Why?
|
Checklist | 1 | 2015 | 827 | 0.300 |
Why?
|
Nurse Practitioners | 3 | 2019 | 271 | 0.290 |
Why?
|
Teaching | 1 | 2015 | 1170 | 0.290 |
Why?
|
Lung Diseases | 4 | 2021 | 1909 | 0.280 |
Why?
|
Arthralgia | 3 | 2022 | 461 | 0.280 |
Why?
|
Hospitalization | 2 | 2024 | 10723 | 0.270 |
Why?
|
Raynaud Disease | 3 | 2014 | 79 | 0.270 |
Why?
|
Needs Assessment | 3 | 2023 | 1139 | 0.270 |
Why?
|
Bone Density | 2 | 2017 | 3551 | 0.270 |
Why?
|
Anticonvulsants | 1 | 2016 | 1906 | 0.260 |
Why?
|
Pulmonary Fibrosis | 6 | 2012 | 505 | 0.260 |
Why?
|
Rheumatoid Factor | 2 | 2020 | 185 | 0.250 |
Why?
|
Consensus | 1 | 2015 | 3123 | 0.250 |
Why?
|
Referral and Consultation | 1 | 2016 | 3600 | 0.210 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2529 | 0.210 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11460 | 0.210 |
Why?
|
Cyclophosphamide | 5 | 2007 | 2218 | 0.200 |
Why?
|
Pain Measurement | 8 | 2023 | 3550 | 0.200 |
Why?
|
Pain | 7 | 2023 | 5073 | 0.200 |
Why?
|
Bronchoalveolar Lavage Fluid | 3 | 2007 | 755 | 0.200 |
Why?
|
Eosinophilia-Myalgia Syndrome | 3 | 1996 | 8 | 0.190 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 289 | 0.190 |
Why?
|
Joints | 2 | 2007 | 322 | 0.190 |
Why?
|
Hemosiderosis | 1 | 2021 | 66 | 0.180 |
Why?
|
Glomerulonephritis, IGA | 1 | 2021 | 63 | 0.180 |
Why?
|
Accreditation | 2 | 2022 | 473 | 0.180 |
Why?
|
Lovastatin | 1 | 2020 | 115 | 0.170 |
Why?
|
Optics and Photonics | 1 | 2002 | 306 | 0.170 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9177 | 0.170 |
Why?
|
Chronic Periodontitis | 1 | 2021 | 101 | 0.170 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3688 | 0.170 |
Why?
|
Prednisone | 2 | 2022 | 1563 | 0.170 |
Why?
|
Proteinuria | 1 | 2003 | 607 | 0.170 |
Why?
|
Tramadol | 1 | 2020 | 60 | 0.170 |
Why?
|
Tomography | 1 | 2002 | 411 | 0.170 |
Why?
|
Acetaminophen | 1 | 2023 | 554 | 0.170 |
Why?
|
Microcirculation | 1 | 2024 | 1273 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 226 | 0.160 |
Why?
|
Personnel Selection | 1 | 2021 | 196 | 0.160 |
Why?
|
Career Mobility | 1 | 2020 | 259 | 0.150 |
Why?
|
Autoantibodies | 2 | 2023 | 2116 | 0.150 |
Why?
|
Feedback | 1 | 2022 | 791 | 0.150 |
Why?
|
Myositis | 2 | 2024 | 271 | 0.150 |
Why?
|
Coronary Circulation | 1 | 2024 | 1569 | 0.150 |
Why?
|
Musculoskeletal System | 1 | 2020 | 188 | 0.150 |
Why?
|
Creatinine | 1 | 2023 | 1899 | 0.150 |
Why?
|
Calcium | 2 | 2023 | 5722 | 0.140 |
Why?
|
Scleroderma, Diffuse | 2 | 2014 | 18 | 0.140 |
Why?
|
Patient Preference | 1 | 2024 | 924 | 0.140 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2002 | 740 | 0.130 |
Why?
|
Secondary Prevention | 1 | 2022 | 1475 | 0.130 |
Why?
|
Program Evaluation | 2 | 2016 | 2495 | 0.130 |
Why?
|
Pain Perception | 1 | 2018 | 196 | 0.130 |
Why?
|
Female | 45 | 2024 | 392644 | 0.130 |
Why?
|
Decision Making | 1 | 2010 | 3929 | 0.130 |
Why?
|
Catastrophization | 1 | 2019 | 348 | 0.130 |
Why?
|
Polymyalgia Rheumatica | 1 | 2016 | 52 | 0.130 |
Why?
|
Systemic Vasculitis | 1 | 2016 | 36 | 0.130 |
Why?
|
Adult | 26 | 2024 | 221177 | 0.130 |
Why?
|
United States | 10 | 2024 | 72334 | 0.130 |
Why?
|
C-Reactive Protein | 3 | 2024 | 3826 | 0.130 |
Why?
|
Teriparatide | 1 | 2017 | 227 | 0.120 |
Why?
|
Scleroderma, Limited | 1 | 2014 | 8 | 0.120 |
Why?
|
Methotrexate | 1 | 2022 | 1719 | 0.120 |
Why?
|
Brassica | 1 | 1994 | 39 | 0.120 |
Why?
|
Sarcoidosis | 2 | 2016 | 521 | 0.120 |
Why?
|
Male | 41 | 2024 | 360804 | 0.120 |
Why?
|
Physicians, Women | 1 | 2020 | 508 | 0.120 |
Why?
|
Middle Aged | 34 | 2024 | 220895 | 0.110 |
Why?
|
Self-Assessment | 1 | 2016 | 396 | 0.110 |
Why?
|
Plant Oils | 1 | 1994 | 198 | 0.110 |
Why?
|
Societies, Medical | 3 | 2024 | 3905 | 0.110 |
Why?
|
Bone Diseases, Metabolic | 1 | 2017 | 409 | 0.110 |
Why?
|
Aged | 22 | 2024 | 169289 | 0.110 |
Why?
|
Severity of Illness Index | 10 | 2023 | 15842 | 0.110 |
Why?
|
Registries | 4 | 2018 | 8224 | 0.110 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1784 | 0.110 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2013 | 36 | 0.110 |
Why?
|
Sex Characteristics | 1 | 2023 | 2639 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 10209 | 0.100 |
Why?
|
Gout | 1 | 2020 | 621 | 0.100 |
Why?
|
Goals | 2 | 2020 | 711 | 0.100 |
Why?
|
Expert Testimony | 1 | 2015 | 364 | 0.100 |
Why?
|
Calcinosis | 1 | 2021 | 1469 | 0.100 |
Why?
|
Learning | 1 | 2022 | 1740 | 0.100 |
Why?
|
Certification | 1 | 2015 | 418 | 0.100 |
Why?
|
Giant Cell Arteritis | 1 | 2016 | 306 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2113 | 0.100 |
Why?
|
Biopsy, Needle | 2 | 2009 | 1626 | 0.100 |
Why?
|
Scleroderma, Localized | 2 | 2009 | 87 | 0.100 |
Why?
|
Immunosuppressive Agents | 4 | 2007 | 4174 | 0.090 |
Why?
|
Bone and Bones | 1 | 2002 | 2568 | 0.090 |
Why?
|
Kidney Failure, Chronic | 1 | 2003 | 2471 | 0.090 |
Why?
|
Risk Factors | 8 | 2022 | 74206 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 942 | 0.090 |
Why?
|
Vital Capacity | 4 | 2018 | 971 | 0.080 |
Why?
|
Antigens, CD | 1 | 2020 | 4003 | 0.080 |
Why?
|
Respiratory Function Tests | 4 | 2024 | 1682 | 0.080 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1642 | 0.080 |
Why?
|
Inflammation | 3 | 2024 | 10773 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39106 | 0.080 |
Why?
|
Femoral Fractures | 1 | 2013 | 375 | 0.080 |
Why?
|
Alcohol Drinking | 1 | 2022 | 4028 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2003 | 2947 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2024 | 64680 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4758 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 1 | 2002 | 4063 | 0.080 |
Why?
|
Fractures, Compression | 1 | 2010 | 131 | 0.080 |
Why?
|
Selection Bias | 1 | 2010 | 359 | 0.070 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2016 | 1723 | 0.070 |
Why?
|
Drug Discovery | 1 | 2016 | 1051 | 0.070 |
Why?
|
History, 20th Century | 1 | 2016 | 2767 | 0.070 |
Why?
|
Vitamins | 1 | 2016 | 1635 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4369 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7390 | 0.070 |
Why?
|
Ultrasonography | 1 | 2020 | 5972 | 0.070 |
Why?
|
Critical Pathways | 1 | 2010 | 474 | 0.070 |
Why?
|
Cohort Studies | 4 | 2022 | 41487 | 0.070 |
Why?
|
Data Collection | 1 | 2015 | 3322 | 0.060 |
Why?
|
Disease Progression | 4 | 2024 | 13506 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3245 | 0.060 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2024 | 32 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26125 | 0.060 |
Why?
|
Tryptophan | 2 | 1996 | 482 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 9486 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2007 | 1596 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2155 | 0.050 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1927 | 0.050 |
Why?
|
Spinal Fractures | 1 | 2010 | 705 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2016 | 3415 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2003 | 6310 | 0.050 |
Why?
|
Double-Blind Method | 5 | 2020 | 12341 | 0.050 |
Why?
|
Anesthetics, Local | 1 | 2010 | 997 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2003 | 135 | 0.050 |
Why?
|
Eosinophils | 1 | 2007 | 950 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58976 | 0.050 |
Why?
|
Sjogren's Syndrome | 1 | 2024 | 237 | 0.050 |
Why?
|
Pregnancy, High-Risk | 1 | 2003 | 122 | 0.050 |
Why?
|
Vitamin D | 1 | 2016 | 3303 | 0.050 |
Why?
|
Ulnar Artery | 1 | 2002 | 15 | 0.050 |
Why?
|
Hemodynamics | 3 | 2016 | 4159 | 0.050 |
Why?
|
Absorption | 1 | 2002 | 242 | 0.050 |
Why?
|
Antihypertensive Agents | 2 | 2003 | 2024 | 0.050 |
Why?
|
Cytokines | 1 | 1997 | 7396 | 0.050 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2007 | 851 | 0.050 |
Why?
|
Peptides, Cyclic | 1 | 2023 | 392 | 0.050 |
Why?
|
Gingival Crevicular Fluid | 1 | 2021 | 94 | 0.050 |
Why?
|
Fetal Death | 1 | 2003 | 435 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 323 | 0.040 |
Why?
|
South Carolina | 2 | 2013 | 100 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2003 | 731 | 0.040 |
Why?
|
Chickens | 1 | 2002 | 859 | 0.040 |
Why?
|
Prospective Studies | 7 | 2019 | 54425 | 0.040 |
Why?
|
Epoprostenol | 1 | 2000 | 247 | 0.040 |
Why?
|
Troponin T | 1 | 2024 | 780 | 0.040 |
Why?
|
Videoconferencing | 1 | 2021 | 203 | 0.040 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2024 | 575 | 0.040 |
Why?
|
Electronics | 1 | 2020 | 318 | 0.040 |
Why?
|
Mass Screening | 2 | 2024 | 5428 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2024 | 999 | 0.040 |
Why?
|
Gout Suppressants | 1 | 2020 | 177 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2021 | 1572 | 0.040 |
Why?
|
Carpal Tunnel Syndrome | 1 | 2001 | 303 | 0.040 |
Why?
|
Lung | 2 | 2014 | 10000 | 0.040 |
Why?
|
Arterial Occlusive Diseases | 1 | 2002 | 748 | 0.040 |
Why?
|
Chemokine CCL3 | 1 | 1997 | 84 | 0.040 |
Why?
|
Chemokine CCL4 | 1 | 1997 | 126 | 0.040 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 1997 | 121 | 0.040 |
Why?
|
Metacarpophalangeal Joint | 1 | 2017 | 82 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2003 | 1302 | 0.030 |
Why?
|
Fingers | 2 | 2002 | 507 | 0.030 |
Why?
|
Ulna | 1 | 2017 | 134 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 1997 | 214 | 0.030 |
Why?
|
Saliva | 1 | 2021 | 828 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15500 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2005 | 1200 | 0.030 |
Why?
|
Blood Pressure | 1 | 2012 | 8481 | 0.030 |
Why?
|
Longitudinal Studies | 4 | 2014 | 14605 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10552 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2024 | 1886 | 0.030 |
Why?
|
CREST Syndrome | 1 | 1995 | 6 | 0.030 |
Why?
|
Patient Participation | 1 | 2024 | 1444 | 0.030 |
Why?
|
Neutrophils | 1 | 2007 | 3767 | 0.030 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2014 | 94 | 0.030 |
Why?
|
Workplace | 1 | 2021 | 863 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2645 | 0.030 |
Why?
|
Total Lung Capacity | 2 | 2007 | 149 | 0.030 |
Why?
|
Radius | 1 | 2017 | 441 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2018 | 495 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2003 | 12974 | 0.030 |
Why?
|
Uric Acid | 1 | 2020 | 807 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20570 | 0.030 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 1994 | 190 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3023 | 0.030 |
Why?
|
Hospitals, University | 2 | 2006 | 563 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2021 | 2696 | 0.030 |
Why?
|
Pre-Eclampsia | 1 | 2003 | 1231 | 0.030 |
Why?
|
Fibrosis | 1 | 2020 | 2049 | 0.030 |
Why?
|
Osteomalacia | 1 | 2013 | 60 | 0.030 |
Why?
|
Coronary Vessels | 1 | 2024 | 3096 | 0.030 |
Why?
|
North Carolina | 1 | 2013 | 325 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12059 | 0.020 |
Why?
|
Connective Tissue Diseases | 1 | 1995 | 285 | 0.020 |
Why?
|
Bone Nails | 1 | 2013 | 220 | 0.020 |
Why?
|
Paraneoplastic Syndromes | 1 | 2013 | 155 | 0.020 |
Why?
|
Peptides | 1 | 2023 | 4358 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1385 | 0.020 |
Why?
|
Fracture Fixation, Intramedullary | 1 | 2013 | 159 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168459 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18395 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5871 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3810 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2003 | 11076 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2002 | 3575 | 0.020 |
Why?
|
Quality of Life | 3 | 2007 | 13367 | 0.020 |
Why?
|
Skin | 1 | 2003 | 4484 | 0.020 |
Why?
|
Forecasting | 1 | 2018 | 2928 | 0.020 |
Why?
|
Young Adult | 2 | 2020 | 59243 | 0.020 |
Why?
|
Administration, Oral | 2 | 2007 | 4021 | 0.020 |
Why?
|
Incidence | 1 | 2007 | 21353 | 0.020 |
Why?
|
Educational Measurement | 1 | 2015 | 1254 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9646 | 0.020 |
Why?
|
Syndrome | 1 | 1994 | 3267 | 0.020 |
Why?
|
Collagen | 1 | 1996 | 2638 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6485 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9326 | 0.020 |
Why?
|
Bronchoalveolar Lavage | 1 | 2007 | 128 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1297 | 0.020 |
Why?
|
Exercise Test | 1 | 2014 | 2127 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8631 | 0.020 |
Why?
|
Motor Activity | 1 | 1996 | 2715 | 0.020 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 273 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4352 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 4989 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13255 | 0.020 |
Why?
|
Leukopenia | 1 | 2006 | 213 | 0.020 |
Why?
|
Depression | 1 | 2005 | 8124 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2002 | 9000 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2024 | 6403 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12725 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5112 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12463 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3808 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2007 | 1814 | 0.010 |
Why?
|
Cognition Disorders | 1 | 1996 | 3979 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20098 | 0.010 |
Why?
|
Risk Assessment | 1 | 2003 | 23995 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 39967 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9610 | 0.010 |
Why?
|
Sympathectomy | 1 | 2002 | 72 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2007 | 970 | 0.010 |
Why?
|
Hypesthesia | 1 | 2001 | 107 | 0.010 |
Why?
|
Median Nerve | 1 | 2001 | 132 | 0.010 |
Why?
|
Pregnancy | 1 | 2003 | 29874 | 0.010 |
Why?
|
Paresthesia | 1 | 2001 | 162 | 0.010 |
Why?
|
Ulcer | 1 | 2002 | 204 | 0.010 |
Why?
|
Antibodies, Antinuclear | 1 | 2002 | 343 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2007 | 1835 | 0.010 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2000 | 273 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4853 | 0.010 |
Why?
|
Cognition | 1 | 1996 | 6990 | 0.010 |
Why?
|
Age of Onset | 1 | 2006 | 3305 | 0.010 |
Why?
|
Saphenous Vein | 1 | 2002 | 516 | 0.010 |
Why?
|
Cardiac Output | 1 | 2000 | 831 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3801 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6343 | 0.010 |
Why?
|
Echocardiography, Doppler | 1 | 2000 | 897 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2000 | 2219 | 0.010 |
Why?
|
Swimming | 1 | 1996 | 208 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 80636 | 0.010 |
Why?
|
Maze Learning | 1 | 1996 | 483 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1996 | 1545 | 0.010 |
Why?
|
Vascular Surgical Procedures | 1 | 2002 | 1489 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1996 | 1900 | 0.010 |
Why?
|
Health Status | 1 | 2005 | 4077 | 0.010 |
Why?
|
Reaction Time | 1 | 1996 | 2082 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 1996 | 22169 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1996 | 6228 | 0.000 |
Why?
|
Disease Models, Animal | 2 | 1996 | 18252 | 0.000 |
Why?
|
Anticoagulants | 1 | 2002 | 4812 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1997 | 2091 | 0.000 |
Why?
|
Body Weight | 1 | 1996 | 4618 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 36426 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1996 | 12795 | 0.000 |
Why?
|
Mice | 2 | 1996 | 81525 | 0.000 |
Why?
|
Prognosis | 1 | 1997 | 29625 | 0.000 |
Why?
|